Positive Results on LAR from DURATION-3 Study Yesterday, Amylin Pharmaceuticals, Inc. (AMLN), Eli Lilly and Company (LLY) and Alkermes, Inc. (ALKS) announced positive results on exenatide once weekly long acting release (LAR) formulation from a phase III head-to-head study which compared LAR with Sanofi-Aventis’ (SNY) Lantus (insulin glargine). The 26 week study was conducted in type II diabetes patients (n=467) who were unable to achieve adequate glucose control on metformin therapy alone or in combination with a sulfonylurea. Results showed that LAR was more effective in reducing blood sugar levels compared to Lantus (6.8% vs. 7%). Moreover, patients on LAR therapy achieved a mean weight loss of 5.8 pounds compared with a mean weight gain of 3.1 pounds in patients treated with Lantus. This is important as data indicate that weight loss helps patients in their efforts to achieve and sustain glycemic ...

For Immediate Release

Chicago, IL - June 9, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amylin Pharmaceuticals (AMLN), Merck (MRK), Glaxo (GSK), Bristol (BMY) and Eli Lilly (LLY).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Monday's Analyst Blog:

Amylin Update Post ADA Meeting

This past weekend, Amylin Pharmaceuticals (AMLN) presented several abstracts and oral presentations at the American Diabetes Association (ADA) meeting in New Orleans. At the meeting, Amylin presented long-term follow-up data from the 74-week open label portion of the DURATION-1 program that demonstrated

...